Volrustomig Priming Regimens Exploratory Phase II Platform Study
← catalyst calendarNCT06448754 · readout in 345 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
180estimated
Sites
77
Countries
Canada, China, France +12
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-08-27 | actual | When the study began enrolling |
| Primary completion | 2027-07-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-07-30 | estimated | The whole study's end, after follow-up |
| First posted | 2024-06-07 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Non-small Cell Lung Cancer
Interventions
- Drug: Volrustomig — also filed as MEDI5752
- Drug: Carboplatin
- Drug: Pemetrexed
- Drug: Ramucirumab
- Drug: Paclitaxel
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
measured From screening (Days -28 to Day -1) up to 2 year 10 months
Confirmed Objective Response rate (ORR)
measured Up to 2 year 10 months
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed